NYSE · ZEPP
Zepp Health financials
$3.96+1.80%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $258.9M | $182.6M | $352.9M | $613.6M | $6.25B |
| Gross profit | $99.2M | $70.2M | $92.4M | $118.9M | $1.31B |
| Gross margin | 38.3% | 38.5% | 26.2% | 19.4% | 20.9% |
| Operating income | -$29.2M | -$47.3M | -$30.4M | -$61.9M | $93.9M |
| Net income | -$40.1M | -$75.7M | -$31.0M | -$43.2M | $137.8M |
| Net margin | −15.5% | −41.5% | −8.8% | −7.0% | 2.2% |
| Diluted EPS | $-0.16 | $-0.29 | $-0.13 | $-0.18 | $2.08 |
| EBITDA | -$24.7M | -$42.2M | -$22.8M | -$53.4M | $145.8M |
| Operating cash flow | -$25.7M | -$24.4M | $42.6M | -$117.1M | -$232.4M |
| Free cash flow | -$26.2M | -$25.8M | $41.0M | -$118.3M | -$278.5M |
| Diluted shares | 254.4M | 258.9M | 243.1M | 246.3M | 66.1M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $57.0M | $91.1M | $133.7M | $886.6M | $230.4M |
| Short-term investments | $0.00 | $997.0K | $5.2M | $34.3M | $3.0M |
| Total debt | $226.9M | $178.8M | $188.7M | $1.65B | $186.5M |
| Total assets | $564.8M | $528.6M | $635.5M | $5.27B | $955.0M |
| Total liabilities | $350.3M | $275.9M | $282.8M | $2.58B | $494.6M |
| Shareholders' equity | $214.5M | $252.7M | $352.8M | $2.68B | $460.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology